

# Prevalence of clopidogrel non-responders among patients scheduled for elective coronary stent placement

Thrombosis and Haemostasis

89, 783-787

DOI: 10.1055/s-0037-1613462

Citation Report

#	ARTICLE	IF	CITATIONS
1	Laboratory monitoring of antiplatelet therapy. , 2001, , 386-406.		1
2	Complete lysis of left ventricular giant thrombus with fibrinolytic therapy in clopidogrel resistant patient. Journal of Thrombosis and Thrombolysis, 2003, 15, 59-63.	2.1	8
3	Clopidogrelâ€™s role in the management of atherosclerotic disease: a focus on acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2003, 1, 507-522.	1.5	0
4	Genetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs. Circulation, 2003, 108, 910-911.	1.6	35
5	Drugâ€™drug interactions involving antiplatelet agents. European Heart Journal, 2003, 24, 1707-1709.	2.2	14
6	Do platelets trigger atherosclerosis?. Thrombosis and Haemostasis, 2003, 90, 971-972.	3.4	24
7	Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thrombosis and Haemostasis, 2004, 92, 1201-1206.	3.4	67
8	Do statins really interfere with clopidogrel-induced platelet function?: Reply. European Heart Journal, 2004, 25, 449.	2.2	0
9	Clopidogrel Resistance. Circulation, 2004, 109, 3064-3067.	1.6	190
10	Assessing the effect of ACE inhibitors on exercise tolerance: a question of study design. European Heart Journal, 2004, 25, 447.	2.2	4
11	Are we making efficient use of clopidogrel?. European Heart Journal, 2004, 25, 454-456.	2.2	11
12	High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. European Heart Journal, 2004, 25, 1903-1910.	2.2	268
13	Surface Expression of Collagen Receptor Fc Receptor-Î/Glycoprotein VI Is Enhanced on Platelets in Type 2 Diabetes and Mediates Release of CD40 Ligand and Activation of Endothelial Cells. Diabetes, 2004, 53, 2117-2121.	0.6	64
14	Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. Circulation, 2004, 109, 166-171.	1.6	449
15	Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. European Heart Journal, 2004, 25, 1898-1902.	2.2	80
16	The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?. Thrombosis Journal, 2004, 2, 1.	2.1	89
17	Resistance to antiplatelet drugs: Is it real or relevant?. Catheterization and Cardiovascular Interventions, 2004, 62, 43-45.	1.7	3
18	Pharmacokinetics of clopidogrel after administration of a high loading dose. Thrombosis and Haemostasis, 2004, 92, 311-316.	3.4	215

#	ARTICLE	IF	CITATIONS
19	Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. Chest, 2004, 126, 234S-264S.	0.8	578
20	P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagulation and Fibrinolysis, 2005, 16, 199-204.	1.0	94
21	Narrative Review: Aspirin Resistance and Its Clinical Implications. Annals of Internal Medicine, 2005, 142, 370.	3.9	135
22	Raising the loading dose of clopidogrel: aiming at the proper target?: reply. European Heart Journal, 2005, 26, 740-741.	2.2	0
24	Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. Journal of Thrombosis and Haemostasis, 2005, 3, 85-92.	3.8	367
25	Determinants of the interindividual variability in response to antiplatelet drugs. Journal of Thrombosis and Haemostasis, 2005, 3, 1597-1602.	3.8	84
26	Therapeutic approaches in arterial thrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 1577-1589.	3.8	74
28	Neurovascular Rescue. Seminars in Vascular Surgery, 2005, 18, 101-109.	2.8	9
29	Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. Translational Research, 2005, 145, 309-315.	2.3	73
30	Aspirin and clopidogrel: Efficacy, treatment, and resistance in coronary artery disease. International Journal of Angiology, 2005, 14, 109-114.	0.6	1
31	Resistance to antiplatelet therapy. Current Cardiology Reports, 2005, 7, 242-248.	2.9	15
32	A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thrombosis and Haemostasis, 2005, 93, 789-791.	3.4	26
33	Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. Thrombosis and Haemostasis, 2005, 93, 1128-1136.	3.4	88
34	Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. European Heart Journal, 2005, 26, 2063-2074.	2.2	69
35	Efficient tyrosine phosphorylation of proteins after activation of platelets with thrombin depends on intact glycoprotein Ib. Platelets, 2005, 16, 453-461.	2.3	5
36	Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment. Diabetes, 2005, 54, 2430-2435.	0.6	492
37	Peri-procedural myocardial injury: 2005 update. European Heart Journal, 2005, 26, 2493-2519.	2.2	286
38	Loading, Pretreatment, and Interindividual Variability Issues With Clopidogrel Dosing. Circulation, 2005, 111, 2557-2559.	1.6	36

#	ARTICLE	IF	CITATIONS
39	Percutaneous coronary intervention: recommendations for good practice and training. Heart, 2005, 91, vi1-vi27.	2.9	38
40	Preclinical and Clinical Studies with Selective Reversible Direct P2Y12Antagonists. Seminars in Thrombosis and Hemostasis, 2005, 31, 195-204.	2.7	249
41	Peripheral Arterial Disease: A Missed Opportunity to Administer Statins so as to Reduce Cardiac Morbidity and Mortality. Current Medicinal Chemistry, 2005, 12, 443-452.	2.4	50
42	Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y12Receptor Antagonist Activity. Seminars in Thrombosis and Hemostasis, 2005, 31, 184-194.	2.7	241
43	Platelet VASP phosphorylation assessment in clopidogrel-treated patients: Lack of agreement between Western blot and flow cytometry. Platelets, 2005, 16, 474-481.	2.3	12
44	Dual Antiplatelet Therapy for Coronary Stenting. Circulation, 2005, 111, 1097-1099.	1.6	7
45	Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention. Circulation, 2005, 111, 3366-3373.	1.6	392
46	Monitoring of Clopidogrel Action: Comparison of Methods. Clinical Chemistry, 2005, 51, 957-965.	3.2	165
47	Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease. Circulation, 2005, 111, e267-71.	1.6	22
48	Resistance to antiplatelet drugs: current status and future research. Expert Opinion on Pharmacotherapy, 2005, 6, 2027-2045.	1.8	65
49	Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets. Circulation, 2005, 111, 1153-1159.	1.6	350
50	Guidelines for Percutaneous Coronary Interventions. European Heart Journal, 2005, 26, 804-847.	2.2	1,408
51	Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12 , and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease. Stroke, 2005, 36, 1394-1399.	2.0	87
52	Platelets and new antiplatelet drugs. Therapy: Open Access in Clinical Medicine, 2005, 2, 465-502.	0.2	8
53	Raising the loading dose of clopidogrel: aiming at the proper target?. European Heart Journal, 2005, 26, 740-741.	2.2	0
54	Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?. European Heart Journal, 2005, 26, 576-583.	2.2	175
55	Antiplatelet Therapy in Neuroendovascular Therapeutics. Neurosurgery Clinics of North America, 2005, 16, 517-540.	1.7	42
56	Structural insights in platelet receptor synergism-antiplatelet therapy in post-ischemic cerebrovascular events. Blood Cells, Molecules, and Diseases, 2005, 34, 248-256.	1.4	7

#	ARTICLE	IF	CITATIONS
57	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 303-304.	0.0	0
58	The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thrombosis Research, 2005, 115, 89-94.	1.7	138
59	Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thrombosis Research, 2005, 115, 101-108.	1.7	154
60	Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thrombosis Research, 2005, 116, 55-66.	1.7	21
62	Clopidogrel and Bleeding After Coronary Artery Bypass Graft Surgery. Annals of Thoracic Surgery, 2005, 80, 928-933.	1.3	105
64	Aspirin Resistance and Atherothrombotic Disease. Journal of the American College of Cardiology, 2005, 46, 986-993.	2.8	179
65	Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 2005, 45, 246-251.	2.8	713
66	The Relation of Dosing to Clopidogrel Responsiveness and the Incidence of High Post-Treatment Platelet Aggregation in Patients Undergoing Coronary Stenting. Journal of the American College of Cardiology, 2005, 45, 1392-1396.	2.8	345
67	Resistance to clopidogrel: A review of the evidence. Journal of the American College of Cardiology, 2005, 45, 1157-1164.	2.8	457
68	Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy. Journal of the American College of Cardiology, 2005, 45, 1748-1752.	2.8	232
69	Matching the Evaluation of the Clinical Efficacy of Clopidogrel to Platelet Function Tests Relevant to the Biological Properties of the Drug. Journal of the American College of Cardiology, 2005, 46, 638-645.	2.8	119
70	Clopidogrel. Journal of the American College of Cardiology, 2005, 46, 646-647.	2.8	12
71	Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis. Journal of the American College of Cardiology, 2005, 46, 1827-1832.	2.8	525
72	Aspirin resistance in stroke: 2004. Journal of the Neurological Sciences, 2005, 229-230, 163-169.	0.6	35
73	Cardiovascular Biomarkers. , 2006, , .		5
74	Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene P2Y12 and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Arterial Disease. Journal of Vascular Surgery, 2006, 43, 640.	1.1	0
75	Clopidogrel use in coronary artery disease. Expert Review of Cardiovascular Therapy, 2006, 4, 7-15.	1.5	6
76	Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets, 2006, 17, 303-310.	2.3	38

#	ARTICLE	IF	CITATIONS
77	Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1895-1900.	2.4	214
78	Controversia terapéutica: clopidogrel y estatinas. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2006, 18, 34-48.	0.8	0
79	Thrombelastography: Current clinical applications and its potential role in interventional cardiology. <i>Platelets</i> , 2006, 17, 509-518.	2.3	99
80	Aspirin and Clopidogrel Resistance. <i>Mayo Clinic Proceedings</i> , 2006, 81, 518-526.	3.0	88
81	Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12inhibitor: A multiple-dose study in healthy humans. <i>Platelets</i> , 2006, 17, 218-226.	2.3	46
82	Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12inhibitor: A single ascending dose study in healthy humans. <i>Platelets</i> , 2006, 17, 209-217.	2.3	101
83	Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2006, 47, 27-33.	2.8	436
84	Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Nonâ€ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1339-1345.	2.8	329
85	Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1742-1750.	2.8	558
87	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). <i>American Heart Journal</i> , 2006, 152, 627-635.	2.7	290
88	The platelet P2 receptors in arterial thrombosis. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 223-227.	1.4	43
89	Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. <i>Thrombosis and Haemostasis</i> , 2006, 96, 767-773.	3.4	45
90	The Clinical Potential of a Point-of-Care Assay to Assess Interindividual Variability in Platelet Aggregation Among Patients Taking Clopidogrel. <i>Critical Pathways in Cardiology</i> , 2006, 5, 103-113.	0.5	1
91	Variability of Response to Clopidogrel. <i>Cardiology in Review</i> , 2006, 14, 136-142.	1.4	27
92	High postâ€treatment platelet reactivity identified lowâ€responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 542-549.	3.8	349
93	Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 539-541.	3.8	11
94	P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 912-914.	3.8	22
95	Diabetes mellitus and platelet function after administration of aspirin and a single 600â€mg dose of clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2566-2568.	3.8	11

#	ARTICLE	IF	CITATIONS
96	Aspirin and Clopidogrel Resistance: Consideration and Management. Journal of Interventional Cardiology, 2006, 19, 439-448.	1.2	51
97	Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4. Pharmaceutical Research, 2006, 23, 2691-2708.	3.5	41
98	Antiplatelet resistance with aspirin and clopidogrel: Is it real and does it matter?. Current Cardiology Reports, 2006, 8, 301-306.	2.9	7
99	Brief review: Coronary drug-eluting stents and anesthesia. Canadian Journal of Anaesthesia, 2006, 53, 1230-1243.	1.6	19
100	Variability in Responsiveness to Clopidogrel in Patients with Intermittent Claudication. European Journal of Vascular and Endovascular Surgery, 2006, 32, 71-75.	1.5	12
101	Clopidogrel Loading Dose (300 Versus 600 mg) Strategies for Patients With Stable Angina Pectoris Subjected to Percutaneous Coronary Intervention. American Journal of Cardiology, 2006, 97, 984-989.	1.6	39
102	Clopidogrel Response Variability, Resistance, or Both?. American Journal of Cardiology, 2006, 98, S18-S24.	1.6	38
103	A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Cardiology, 2006, 2, 255-267.	1.2	1
104	Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal, 2006, 27, 2420-2425.	2.2	453
105	Clopidogrel Resistance: Implications for Coronary Stenting. Current Pharmaceutical Design, 2006, 12, 1261-1269.	1.9	20
106	Thromboelastography: Potential bedside tool to assess the effects of antiplatelet therapy?. Platelets, 2006, 17, 385-392.	2.3	74
107	Clopidogrel Resistance: Myth or Reality?. Journal of Cardiovascular Pharmacology and Therapeutics, 2006, 11, 47-53.	2.0	30
108	Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Cmaj, 2006, 174, 1715-1722.	2.0	177
109	Clopidogrel resistance: fact and fiction. Future Cardiology, 2006, 2, 215-228.	1.2	19
110	Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European Heart Journal, 2006, 27, 1166-1173.	2.2	513
111	Clopidogrel resistance / Clopidogrel-Resistenz. Das Medizinische Laboratorium, 2006, 30, 310-316.	0.0	2
112	Clopidogrel Response Variability and Future Therapies. Circulation, 2006, 114, e600-6.	1.6	106
113	Drug Insight: clopidogrel nonresponsiveness. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 387-395.	3.3	105

#	ARTICLE	IF	CITATIONS
114	Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. <i>Platelets</i> , 2006, 17, 250-258.	2.3	65
115	REGULATION OF PLATELET FUNCTIONS BY P2 RECEPTORS. <i>Annual Review of Pharmacology and Toxicology</i> , 2006, 46, 277-300.	9.4	245
116	Does prasugrel achieve superior platelet inhibition when compared with clopidogrel in patients with CAD?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 648-649.	3.3	0
117	Aspirin and clopidogrel resistance: an emerging clinical entity. <i>European Heart Journal</i> , 2006, 27, 647-654.	2.2	286
118	Determination of Clopidogrel Resistance by Whole Blood Platelet Aggregometry and Inhibitors of the P2Y12 Receptor. <i>Clinical Chemistry</i> , 2006, 52, 383-388.	3.2	67
119	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 939-953.	1.5	1
120	Significance of Aspirin and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions. <i>Current Vascular Pharmacology</i> , 2007, 5, 135-140.	1.7	2
121	Variability in response to clopidogrel: where is the threshold for 'low response'?. <i>European Heart Journal</i> , 2007, 28, 515-516.	2.2	0
122	The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. <i>Country Review Ukraine</i> , 2007, 9, D10-D19.	0.8	1
124	A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. <i>European Heart Journal</i> , 2007, 28, 1814-1819.	2.2	198
125	Brain Injury Secondary to Carotid Intervention. <i>Journal of Endovascular Therapy</i> , 2007, 14, 219-231.	1.5	14
126	Monitoring of the Antiplatelet Drugs Effect in Patients with Coronary Artery Disease: What is the Real Clinical Impact?. <i>Current Vascular Pharmacology</i> , 2007, 5, 293-301.	1.7	10
127	Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2007, 12, 205-212.	2.0	36
128	Platelet Response to Clopidogrel Is Attenuated in Diabetic Patients Undergoing Coronary Stent Implantation. <i>Diabetes Care</i> , 2007, 30, 372-374.	8.6	143
129	The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. <i>Thrombosis and Haemostasis</i> , 2007, 98, 201-209.	3.4	32
130	Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 782-791.	1.5	4
131	Platelet function in clopidogrel-treated patients with acute coronary syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 335-339.	1.0	39
132	Variability in response to clopidogrel: where is the threshold for 'low response'?: reply. <i>European Heart Journal</i> , 2007, 28, 516-516.	2.2	1



#	ARTICLE	IF	CITATIONS
133	Point-of-Care Monitoring for Optimal Antiplatelet Therapy in Acute Clinical Settings. Point of Care, 2007, 6, 208-212.	0.4	1
134	New developments in oral antiplatelet therapy. Country Review Ukraine, 2007, 9, D20-D27.	0.8	20
135	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERiFY Thrombosis risk ASsessment (VERITAS) study. Thrombosis Research, 2007, 119, 277-284.	1.7	198
136	Clopidogrel resistance?. Thrombosis Research, 2007, 120, 311-321.	1.7	151
137	The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thrombosis Research, 2007, 120, 353-359.	1.7	25
138	Measuring antiplatelet drug effects in the laboratory. Thrombosis Research, 2007, 120, 323-336.	1.7	171
139	Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thrombosis Research, 2007, 120, 893-899.	1.7	77
140	Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thrombosis Research, 2007, 121, 107-115.	1.7	51
141	Antiplatelet agents make a comeback in ST-elevation myocardial infarction. American Heart Journal, 2007, 154, 603-606.	2.7	0
142	A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. American Heart Journal, 2007, 153, 66.e9-66.e16.	2.7	483
143	Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. American Heart Journal, 2007, 154, 221-231.	2.7	390
144	Clopidogrel-Induced Platelet Inhibition Cannot Be Detected by the Platelet Function Analyzer-100 System in Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2007, 16, 199-202.	1.6	27
145	Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine. International Journal of Cardiology, 2007, 114, 101-102.	1.7	5
146	Platelet non-responsiveness to dual antiplatelet therapy and relation to coronary disease among diabetes patients. International Journal of Cardiology, 2007, 118, 418-420.	1.7	1
147	Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis, 2007, 195, e217-e223.	0.8	42
148	Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel. Thrombosis Research, 2007, 119, 355-360.	1.7	147
149	Variability in Individual Responsiveness to Clopidogrel. Journal of the American College of Cardiology, 2007, 49, 1505-1516.	2.8	886
150	Does Glycoprotein IIIa Gene (PIA) Polymorphism Influence Clopidogrel Resistance?. Drugs and Aging, 2007, 24, 345-350.	2.7	11

#	ARTICLE	IF	CITATIONS
151	ADP Receptor Antagonism. American Journal of Cardiovascular Drugs, 2007, 7, 423-432.	2.2	52
152	Clopidogrel poor responders: An objective definition based on Bayesian classification. Platelets, 2007, 18, 428-435.	2.3	25
153	Clopidogrel resistance – The cardiologist's perspective. Platelets, 2007, 18, 175-181.	2.3	12
154	Clopidogrel Resistance. Heart Lung and Circulation, 2007, 16, S17-S28.	0.4	24
155	Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology, 2007, 49, 2312-2317.	2.8	607
156	Platelet Function Monitoring in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1822-1834.	2.8	437
157	RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology, 2007, 3, 52-59.	0.8	3
159	High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thrombosis and Haemostasis, 2007, 97, 282-287.	3.4	102
160	Hyperresponsiveness of platelets in ischemic stroke. Thrombosis and Haemostasis, 2007, 97, 974-978.	3.4	60
161	Clinical Tests of Platelet Function. , 2007, , 445-474.		14
162	The VerifyNow System. , 2007, , 509-518.		11
163	Thienopyridines in cardiovascular disease: Focus on Clopidogrel resistance. Thrombosis and Haemostasis, 2007, 97, 385-393.	3.4	95
164	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 2007, 98, 838-843.	3.4	203
167	Stent thrombosis with drug-eluting stents: A re-examination of the evidence. Catheterization and Cardiovascular Interventions, 2007, 69, 782-789.	1.7	25
168	Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently. Clinical Pharmacology and Therapeutics, 2007, 81, 735-741.	4.7	295
169	Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?. Journal of Thrombosis and Haemostasis, 2007, 5, 884-886.	3.8	23
170	Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. Journal of Thrombosis and Haemostasis, 2007, 5, 1839-1847.	3.8	180
171	Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis, 2007, 5, 2429-2436.	3.8	668

#	ARTICLE	IF	CITATIONS
172	The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. Journal of Thrombosis and Haemostasis, 2008, 6, 54-61.	3.8	200
173	Measuring Aspirin Resistance, Clopidogrel Responsiveness, and Postprocedural Markers of Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 99, 1518-1522.	1.6	48
174	Effects of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) on Platelet Aggregation and P-Selectin Expression in Patients Undergoing Coronary Artery Stent Implantation. American Journal of Cardiology, 2007, 100, 610-614.	1.6	47
175	The "Clopidogrel Resistance" Trap. American Journal of Cardiology, 2007, 100, 1044-1046.	1.6	22
176	Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Duration, Resistance, Alternatives, and Management of Surgical Patients. American Journal of Cardiology, 2007, 100, S18-S25.	1.6	28
179	Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. Netherlands Heart Journal, 2007, 15, 148-150.	0.8	8
180	Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Netherlands Heart Journal, 2007, 15, 382-386.	0.8	8
181	A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y <sub>12</sub> inhibitor, compared with clopidogrel in healthy humans. British Journal of Clinical Pharmacology, 2007, 63, 421-430.	2.4	134
182	A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. Journal of Thrombosis and Thrombolysis, 2007, 23, 213-222.	2.1	51
183	Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. Journal of Thrombosis and Thrombolysis, 2007, 24, 15-21.	2.1	18
184	Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y <sub>1</sub> and the P2Y <sub>12</sub> receptor and is correlated with protein expression of P2Y <sub>12</sub> . Purinergic Signalling, 2007, 3, 195-201.	2.2	16
185	Clinical Trials Update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovascular Drugs and Therapy, 2007, 21, 459-465.	2.6	26
186	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. Cardiovascular Drugs and Therapy, 2008, 22, 313-320.	2.6	25
189	Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. European Journal of Clinical Pharmacology, 2008, 64, 589-597.	1.9	41
190	Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thrombosis Journal, 2008, 6, 1.	2.1	30
191	The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response. JACC: Cardiovascular Interventions, 2008, 1, 620-627.	2.9	114
192	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. Clinical Cardiology, 2008, 31, 121-127.	1.8	7
193	The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance. Clinical Pharmacology and Therapeutics, 2008, 84, 236-242.	4.7	270

#	ARTICLE	IF	CITATIONS
194	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2008, 101, 1088-1093.	1.6	194
195	Comparison of Higher Clopidogrel Loading and Maintenance Dose to Standard Dose on Platelet Function and Outcomes After Percutaneous Coronary Intervention Using Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2008, 102, 401-403.	1.6	29
196	Effectiveness of Reloading to Overcome Clopidogrel Nonresponsiveness in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2008, 102, 524-529.	1.6	35
197	P2 receptors, platelet function and pharmacological implications. <i>Thrombosis and Haemostasis</i> , 2008, 99, 466-472.	3.4	250
199	Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprotection and atherothrombosis in ApoE-deficient mice in vivo. <i>Thrombosis and Haemostasis</i> , 2008, 99, 190-195.	3.4	46
200	Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1925-1934.	2.8	523
201	Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1968-1977.	2.8	186
202	The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1826-1833.	2.8	49
203	Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 743-751.	1.6	8
204	Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. <i>European Heart Journal</i> , 2008, 29, 992-1000.	2.2	593
205	Antiplatelet drug nonresponsiveness. <i>American Heart Journal</i> , 2008, 155, 591-599.	2.7	52
206	Current antiplatelet therapies: Benefits and limitations. <i>American Heart Journal</i> , 2008, 156, 3S-9S.	2.7	48
207	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. <i>Platelets</i> , 2008, 19, 595-604.	2.3	101
208	Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 91-112.	2.2	21
209	Current concepts about inhibition of platelet aggregation. <i>Platelets</i> , 2008, 19, 565-570.	2.3	11
210	Chapter 64 Antithrombotic agents for stroke prevention. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 94, 1277-1294.	1.8	2
211	Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting. <i>American Journal of Neuroradiology</i> , 2008, 29, 786-791.	2.4	95
212	Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2008, 30, 426-435.	2.2	192

#	ARTICLE	IF	CITATIONS
213	Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. <i>European Heart Journal</i> , 2008, 29, 1635-1643.	2.2	29
214	Antiplatelet Drugs. <i>Chest</i> , 2008, 133, 199S-233S.	0.8	478
215	The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice. <i>Neurological Research</i> , 2008, 30, 669-677.	1.3	3
216	Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. <i>Platelets</i> , 2008, 19, 335-341.	2.3	28
217	Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin- and thienopyridine-treated patients. <i>Clinical Hemorheology and Microcirculation</i> , 2008, 40, 295-302.	1.7	9
218	Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. <i>Heart</i> , 2008, 94, 743-747.	2.9	55
219	New antiplatelet therapies in development. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, S11-S15.	1.0	2
221	CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. <i>Pharmacogenomics</i> , 2008, 9, 1251-1259.	1.3	209
222	Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance. <i>Postgraduate Medical Journal</i> , 2008, 84, 217-219.	1.8	6
223	Thienopyridine Therapy Influences Late Outcome After Coronary Stent Implantation. <i>Angiology</i> , 2008, 59, 172-178.	1.8	11
224	Dual antiplatelet therapy in the drug-eluting stent era. <i>Country Review Ukraine</i> , 2008, 10, D38-D44.	0.8	2
225	Variability of response to antiplatelet therapy. <i>Country Review Ukraine</i> , 2008, 10, A21-A27.	0.8	12
226	Testing antiplatelet therapy. <i>Country Review Ukraine</i> , 2008, 10, A28-A34.	0.8	46
227	Thienopyridine Response Variability and Resistance. , 0, , 77-93.		0
228	Unmet needs in antiplatelet therapy. <i>Country Review Ukraine</i> , 2008, 10, D3-D11.	0.8	7
229	Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. <i>Thrombosis and Haemostasis</i> , 2008, 99, 121-126.	3.4	265
230	Prasugrel. <i>Cardiology in Review</i> , 2008, 16, 314-318.	1.4	16
231	Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. <i>Future Cardiology</i> , 2008, 4, 33-55.	1.2	17

#	ARTICLE	IF	CITATIONS
232	Clinical implications of clopidogrel resistance. Thrombosis and Haemostasis, 2008, 100, 196-203.	3.4	79
233	ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION. Rational Pharmacotherapy in Cardiology, 2008, 4, 23-29.	0.8	1
234	Antiplatelet Resistance“Does it Exist and how to Measure it?. Clinical Medicine Cardiology, 2009, 3, CMC.S2159.	0.1	6
235	Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. Vascular Health and Risk Management, 2009, 5, 475.	2.3	5
236	Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome. Clinical Medicine Therapeutics, 2009, 1, CMT.S1170.	0.1	1
237	Variability in aggregometry response before and after initiation of clopidogrel therapy. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 673-679.	1.2	5
238	Clopidogrel plus PPIs“a dangerous combination?. Nature Reviews Cardiology, 2009, 6, 392-394.	13.7	11
239	Personalized medicine and antiplatelet therapy: ready for prime time?. European Heart Journal, 2009, 30, 1943-1963.	2.2	37
240	Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future Cardiology, 2009, 5, 237-246.	1.2	1
241	Aprotinin reduces the antiplatelet effect of clopidogrel. Interactive Cardiovascular and Thoracic Surgery, 2009, 9, 178-181.	1.1	10
242	Platelet activity: an obstacle for successful PCI. Nature Reviews Cardiology, 2009, 6, 391-392.	13.7	15
244	Effects of clopidogrel on “aspirin specific“pathways of platelet inhibition. Platelets, 2009, 20, 386-390.	2.3	34
245	The Role of Aspirin in Cardiovascular Disease Prevention in Women. American Journal of Lifestyle Medicine, 2009, 3, 123-134.	1.9	3
246	Current Controversies in the Pharmacogenomics of Clopidogrel. Progress in Cardiovascular Nursing, 2009, 24, 105-109.	0.4	1
247	Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: A randomized, open-label, crossover study in healthy Korean male subjects. Clinical Therapeutics, 2009, 31, 793-803.	2.5	44
248	Variability in Responsiveness to Oral Antiplatelet Therapy. American Journal of Cardiology, 2009, 103, 27A-34A.	1.6	132
249	Advances in Antiplatelet Therapy: Agents in Clinical Development. American Journal of Cardiology, 2009, 103, 40A-51A.	1.6	88
250	Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in Koreans. American Journal of Cardiology, 2009, 104, 46-51.	1.6	93

#	ARTICLE	IF	CITATIONS
251	Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. American Journal of Cardiology, 2009, 104, 525-530.	1.6	54
252	Oral Antiplatelet Therapy in Unstable Angina/Nonâ€“ST-Segment Elevation Myocardial Infarction, ST-Segment Elevation Myocardial Infarction, and Percutaneous Coronary Intervention: Is it Time for a Guideline Update?. American Journal of Cardiology, 2009, 104, 4C-8C.	1.6	0
253	Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. Catheterization and Cardiovascular Interventions, 2009, 73, 1-14.	1.7	36
254	Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clinical Research in Cardiology, 2009, 98, 533-540.	3.3	36
255	Contemporary issues on clopidogrel therapy. Internal and Emergency Medicine, 2009, 4, 201-211.	2.0	1
256	Prasugrel: Clinical development and therapeutic application. Advances in Therapy, 2009, 26, 999-1011.	2.9	10
257	Endovascular occlusion of intracranial wide-necked aneurysms with stenting (Neuroform) and coiling: mid-term and long-term results. Neuroradiology, 2009, 51, 401-409.	2.2	103
258	Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Fundamental and Clinical Pharmacology, 2009, 23, 1-9.	1.9	11
259	Clopidogrel response variability: Current status and future directions. Thrombosis and Haemostasis, 2009, 102, 07-14.	3.4	114
260	Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease. Biomedicine and Pharmacotherapy, 2009, 63, 608-612.	5.6	2
261	Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thrombosis Research, 2009, 124, 46-51.	1.7	38
262	The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thrombosis Research, 2009, 123, 874-880.	1.7	36
263	Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome. Thrombosis Research, 2009, 124, 678-682.	1.7	3
264	Clopidogrel resistance: A diagnostic challenge. International Journal of Cardiology, 2009, 131, 267-268.	1.7	5
265	Clopidogrel resistance: A diagnostic challenge: Reply. International Journal of Cardiology, 2009, 131, 268-269.	1.7	1
266	Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. International Journal of Cardiology, 2009, 133, 341-345.	1.7	78
267	The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. International Journal of Cardiology, 2009, 134, 351-355.	1.7	44
268	Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. American Heart Journal, 2009, 157, 562.e1-562.e9.	2.7	81



#	ARTICLE	IF	CITATIONS
270	Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?. Journal of Clinical Pharmacology, 2009, 49, 506-512.	2.0	39
271	Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nature Reviews Cardiology, 2009, 6, 273-282.	13.7	90
272	Ticagrelor: The First Reversibly Binding Oral P2Y <sub>12</sub> Receptor Antagonist. Cardiovascular Therapeutics, 2009, 27, 259-274.	2.5	304
273	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics, 2009, 10, 1799-1817.	1.3	100
274	Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coronary Artery Disease, 2009, 20, 207-213.	0.7	12
275	Variability in Platelet Response to the Antiplatelet Agents Aspirin and Clopidogrel. Critical Pathways in Cardiology, 2009, 8, 20-28.	0.5	9
276	Functional variability of platelet response to clopidogrel correlates with P2Y <sub>12</sub> receptor occupancy. Thrombosis and Haemostasis, 2009, 101, 116-122.	3.4	25
277	Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y <sub>12</sub> analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry. Blood Coagulation and Fibrinolysis, 2010, 21, 46-52.	1.0	27
278	Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clinical Research in Cardiology, 2010, 99, 743-752.	3.3	46
279	Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis, 2010, 29, 8-24.	2.1	24
280	Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2010, 30, 200-209.	2.1	5
281	Current strategies in antiplatelet therapy – Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. , 2010, 127, 95-107.		18
282	Drug Interaction Between Clopidogrel and Proton Pump Inhibitors. Pharmacotherapy, 2010, 30, 275-289.	2.6	26
283	Bioequivalence of two tablet formulations of clopidogrel in healthy argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study. Clinical Therapeutics, 2010, 32, 161-170.	2.5	25
285	Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2010, 8, 923-933.	3.8	113
286	Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. Journal of Thrombosis and Haemostasis, 2010, 8, 2577-2579.	3.8	14
287	Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. British Journal of Clinical Pharmacology, 2010, 70, 65-77.	2.4	127
288	Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor. Vascular Health and Risk Management, 2010, 6, 419.	2.3	20



#	ARTICLE	IF	CITATIONS
289	Determination of the Prevalence of Aspirin and Clopidogrel Resistances in Patients with Coronary Artery Disease by using Various Platelet-function Tests. <i>Annals of Laboratory Medicine</i> , 2010, 30, 460-468.	2.5	15
290	ADP-receptor blockade: A case for personalised pharmacotherapy?. <i>Thrombosis and Haemostasis</i> , 2010, 103, 496-506.	3.4	17
291	Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. <i>Thrombosis and Haemostasis</i> , 2010, 104, 587-292.	3.4	64
292	Problems of contemporary antiplatelet treatment. <i>Postepy W Kardiologii Interwencyjnej</i> , 2010, 1, 21-29.	0.2	0
294	Routine Platelet Testing Should Not Be Performed on All Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 284-288.	3.9	1
296	Long-Term Aspirin and Clopidogrel Response Evaluated by Light Transmission Aggregometry, VerifyNow, and Thrombelastography in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Chemistry</i> , 2010, 56, 839-847.	3.2	52
297	Ticagrelor Effectively and Reversibly Blocks Murine Platelet P2Y <sub>12</sub> -Mediated Thrombosis and Demonstrates a Requirement for Sustained P2Y <sub>12</sub> Inhibition to Prevent Subsequent Neointima. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2385-2391.	2.4	50
298	Pharmacogenetics guided anticoagulation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, S119-27.	2.3	0
299	Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S7-S17.	1.0	4
300	Perioperative assessment of platelet function in patients under antiplatelet therapy. <i>Expert Review of Medical Devices</i> , 2010, 7, 625-637.	2.8	16
301	Engineering and Characterization of a Chimeric Anti-platelet Glycoprotein Ib/α Monoclonal Antibody and Preparation of Its Fab Fragment. <i>Hybridoma</i> , 2010, 29, 125-132.	0.4	7
302	VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. <i>Platelets</i> , 2010, 21, 94-100.	2.3	17
303	Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y <sub>12</sub> antagonists. <i>Current Drug Targets</i> , 2010, 11, 380-391.	2.1	7
304	Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. <i>European Heart Journal</i> , 2010, 31, 59-66.	2.2	94
305	Benefits of and safety concerns associated with drug-eluting coronary stents. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 449-470.	1.5	24
306	Safety evaluation of tirofiban. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 801-819.	2.4	6
307	Clopidogrel non-responsiveness and risk of cardiovascular morbidity. <i>Thrombosis and Haemostasis</i> , 2010, 103, 00-00.	3.4	177
308	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 919-933.	2.8	1,058

#	ARTICLE	IF	CITATIONS
309	Coronary Stents. Journal of the American College of Cardiology, 2010, 56, S1-S42.	2.8	447
310	Resistance to aspirin: Prevalence, mechanisms of action and association with thromboembolic events. A narrative review. Farmacia Hospitalaria (English Edition), 2010, 34, 32-43.	0.0	2
311	Antiplatelet therapy and vascular disease: an update. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 249-275.	2.1	16
312	The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats. Thrombosis Research, 2010, 125, e93-e99.	1.7	6
313	Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thrombosis and Haemostasis, 2010, 103, 151-159.	3.4	126
314	Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. American Heart Journal, 2010, 159, 891-898.e1.	2.7	36
315	Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis, 2010, 213, 256-262.	0.8	50
316	Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 49-61.	1.4	5
318	Clopidogrel Response Variability and Its Correlation with Early Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention. Pharmacology, 2011, 87, 321-330.	2.2	3
319	The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology, 2011, 8, 547-559.	13.7	84
320	Review: Antiplatelet Therapy in Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 24-42.	2.0	9
321	Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention: A case-control study. American Heart Journal, 2011, 162, 363-371.	2.7	7
322	Acute Multi-Vessel Coronary Stent Thrombosis. Journal of Emergency Medicine, 2011, 41, e43-e48.	0.7	2
323	Clopidogrel Resistance: Identifying and Overcoming a Barrier to Effective Antiplatelet Treatment. Cardiovascular Therapeutics, 2011, 29, e100-e111.	2.5	30
325	Very Late Stent Thrombosis due to Neointimal Rupture After Paclitaxel-Eluting Stent Implantation. Korean Circulation Journal, 2011, 41, 754.	1.9	4
326	The importance of bioequivalence study: focus on clopidogrel. Medical Journal of Indonesia, 0, , 149.	0.5	0
327	Clopidogrel response variability and the advent of personalised antiplatelet therapy. Thrombosis and Haemostasis, 2011, 106, 265-271.	3.4	29
328	Monitoring of antiplatelet therapy. Hamostaseologie, 2011, 31, 41-51.	1.9	25

#	ARTICLE	IF	CITATIONS
329	Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2011, 106, 141-148.	3.4	15
330	The Effect of St John's Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 86-93.	1.9	77
331	Interactions Between Clopidogrel and Proton Pump Inhibitors: A Review of Evidence. <i>Current Medicinal Chemistry</i> , 2011, 18, 2386-2400.	2.4	8
332	Resistance to aspirin and clopidogrel therapy. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 1-18.	1.3	16
333	Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. , 2011, 129, 267-289.		52
334	Effect of cytochrome P450 3A5 polymorphism on platelet reactivity after treatment with clopidogrel in patients scheduled for percutaneous coronary intervention. <i>Egyptian Heart Journal</i> , 2011, 63, 23-31.	1.2	1
335	Clopidogrel in acute coronary syndromes: Where are we now?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 766-773.	3.4	6
336	Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 429-436.	5.1	91
337	Genetic determinants of platelet response to clopidogrel. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 459-466.	2.1	69
338	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. <i>Biomarkers in Medicine</i> , 2011, 5, 9-30.	1.4	3
339	Comparison of a Point-of-Care Platelet Function Testing to Light Transmission Aggregometry in Patients Undergoing Percutaneous Coronary Intervention Pretreated With Aspirin and Clopidogrel. <i>Point of Care</i> , 2011, 10, 35-39.	0.4	3
340	Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 561-569.	0.5	34
341	Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. <i>British Journal of Anaesthesia</i> , 2011, 107, 966-971.	3.4	29
342	Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2012, 23, 523-527.	0.7	7
343	Platelet Function Profile Post-Clopidogrel Therapy in Patients With Type 2 Diabetes Undergoing Coronary Stent Implantation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 249-257.	1.7	2
344	The Pattern of Platelet Response to Clopidogrel in Iranian Patients After Percutaneous Coronary Intervention. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1098-1105.	2.0	3
345	Brachial artery endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction. <i>Platelets</i> , 2012, 23, 202-210.	2.3	8
346	Prevalence of poor biological response to clopidogrel. <i>Thrombosis and Haemostasis</i> , 2012, 107, 494-506.	3.4	81

#	ARTICLE	IF	CITATIONS
347	Development and Clinical use of Prasugrel and Ticagrelor. Current Pharmaceutical Design, 2012, 18, 5240-5260.	1.9	27
348	Overview of platelet functional testing methods and their controversial role in the clopidogrel-treated patient. Interventional Cardiology, 2012, 4, 537-547.	0.0	0
349	A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs. Current Pharmaceutical Design, 2012, 18, 1625-1634.	1.9	1
350	Therapeutic Potential and Strategies Against Leukocyte-Platelet Interaction in Atherosclerosis. Current Vascular Pharmacology, 2012, 10, 550-554.	1.7	4
351	An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors. Current Drug Metabolism, 2012, 13, 225-235.	1.2	14
352	Review of ticagrelor in the management of acute coronary syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1315-1325.	3.3	1
353	Clinical Predictors of High Posttreatment Platelet Reactivity to Clopidogrel in Koreans. Cardiovascular Therapeutics, 2012, 30, 5-11.	2.5	54
354	Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thrombosis Research, 2012, 129, 623-628.	1.7	38
355	Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile of the Oral Antiplatelet Agent Ticagrelor. Clinical Pharmacokinetics, 2012, 51, 305-318.	3.5	53
356	A Therapeutic Window for Platelet Reactivity for Patients Undergoing Elective Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 281-289.	2.9	82
357	Aspirin Prophylaxis for the Prevention of Thrombosis: Expectations and Limitations. Thrombosis, 2012, 2012, 1-9.	1.4	8
358	Oral antiplatelet therapy in acute coronary syndromes: update 2012. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 79-86.	1.0	8
359	Clinical Implications of Genetic Admixture in Hispanic Puerto Ricans: Impact on the Pharmacogenetics of CYP2C19 and PON1. , 2012, , .		5
360	Platelet Function after Cessation of Chronic Clopidogrel Therapy. American Surgeon, 2012, 78, 51-56.	0.8	6
361	A Comparison of Two Brands of Clopidogrel in Patients With Drug-Eluting Stent Implantation. Korean Circulation Journal, 2012, 42, 458.	1.9	5
362	Evolving role of platelet function testing in coronary artery interventions. Vascular Health and Risk Management, 2012, 8, 65.	2.3	15
363	A Comparison of <sc>INNOVANCE</sc>Â® <sc>PFA P</sc>2<sc>Y</sc> and <sc>V</sc>erify<sc>N</sc>ow <sc>P</sc>2<sc>Y</sc>12 Assay for the Assessment of Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention. Journal of Clinical Laboratory Analysis, 2012, 26, 262-266.	2.1	13
364	Platelet Function and Inhibition in Ischemic Heart Disease. Current Cardiology Reports, 2012, 14, 457-467.	2.9	15

#	ARTICLE	IF	CITATIONS
365	Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 2-10.	1.9	7
366	The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. <i>Biochemical Pharmacology</i> , 2012, 83, 903-908.	4.4	31
367	Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. , 2012, 134, 246-259.		28
368	Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 346-354.	2.4	3
369	Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 975-984.	1.5	4
370	Clopidogrel Responsiveness in Stroke Patients on a Chronic Aspirin Regimen. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, 725-732.	1.6	8
371	Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 517-527.	1.6	94
372	The <sc>P2Y</sc> receptors and thrombosis. <i>Environmental Sciences Europe</i> , 2013, 2, 241-253.	5.5	3
373	Antiplatelet Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 5-18.	1.7	12
374	Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1547-1556.	1.5	4
375	Assessing post-treatment platelet reactivity: a focus on patient selection and setting. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1557-1566.	1.5	1
376	Platelet-Function Testing in Patients Undergoing Neurovascular Procedures: Caught between a Rock and a Hard Place. <i>American Journal of Neuroradiology</i> , 2013, 34, 730-734.	2.4	30
377	Perioperative assessment of platelet function by Thromboelastograph® Platelet Mapping®, in cardiovascular patients undergoing non-cardiac surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 23-30.	2.1	34
378	Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: Effects on clopidogrel response. <i>Indian Heart Journal</i> , 2013, 65, 158-167.	0.5	33
379	Relationship of <b>CYP2C19*2</b> and <b>CYP2C19*3</b> Gene Polymorphism with Clopidogrel Response Variability and Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention. <i>Pharmacology</i> , 2013, 91, 165-172.	2.2	17
380	Atherothrombosis and Coronary Artery Disease. , 2013, , 653-668.		0
381	Smoking: Harm reduction versus abstinence. <i>Journal of the American Academy of Nurse Practitioners</i> , 2013, 25, 1-2.	1.4	1
382	Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. <i>Platelets</i> , 2013, 24, 297-302.	2.3	33

#	ARTICLE	IF	CITATIONS
383	CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS OF PATIENTS WITH STENT THROMBOSIS. Acta Medica Medianae, 2013, , 5-11.	0.1	0
384	Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. BioMed Research International, 2013, 2013, 1-5.	1.9	20
385	Influence of Genetic Variations on Levels of Inflammatory Markers of Healthy Subjects at Baseline and One Week after Clopidogrel Therapy; Results of a Preliminary Study. International Journal of Molecular Sciences, 2013, 14, 16402-16413.	4.1	1
386	Prasugrel Versus Clopidogrel. Journal of Cardiovascular Nursing, 2013, 28, 483-494.	1.1	2
387	Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. Platelets, 2013, 24, 151-155.	2.3	8
388	Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300mg loading dose of clopidogrel, measured by thrombelastography. Heart Asia, 2013, 5, 66-69.	1.1	4
389	The Influence of Anti-Platelet Resistance on the Development of Cerebral Ischemic Lesion after Carotid Artery Stenting. Yonsei Medical Journal, 2013, 54, 288.	2.2	29
390	Pharmacokinetics of 600 mg loading dose of clopidogrel in patients undergoing percutaneous coronary intervention. African Journal of Pharmacy and Pharmacology, 2013, 7, 574-584.	0.3	2
391	High-Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e78549.	2.5	7
392	Comparison of a New P2Y12 Receptor Specific Platelet Aggregation Test with Other Laboratory Methods in Stroke Patients on Clopidogrel Monotherapy. PLoS ONE, 2013, 8, e69417.	2.5	19
393	P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes. Hamostaseologie, 2014, 34, 20-28.	1.9	4
394	A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. Clinical Research in Cardiology, 2014, 103, 968-975.	3.3	10
395	Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2014, 12, 1289-1303.	1.5	4
396	Platelet reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2014, 12, 736-747.	3.8	83
397	Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. Molecular Biology Reports, 2014, 41, 7265-7271.	2.3	15
398	Aspirin and clopidogrel resistance using the cone and plate(let) analyser in Indian patients with coronary artery disease. Heart Asia, 2014, 6, 159-162.	1.1	6
399	Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease. PLoS ONE, 2014, 9, e110188.	2.5	19
400	Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. Journal of NeuroInterventional Surgery, 2014, 6, 320-322.	3.3	57



#	ARTICLE	IF	CITATIONS
401	Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 63, 339-350.	1.9	64
402	CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease. <i>Indian Heart Journal</i> , 2014, 66, 16-24.	0.5	11
403	Thienopyridines resistance and recovery of platelet function after discontinuation of thienopyridines in cardiac surgery patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 45, 165-170.	1.4	34
404	Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1041-1047.	1.9	23
405	The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance. <i>Egyptian Heart Journal</i> , 2014, 66, 259-262.	1.2	2
406	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. <i>Scientific Reports</i> , 2015, 5, 13789.	3.3	19
407	Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Japanese Patients With Stable Coronary Artery Disease. <i>Circulation Journal</i> , 2015, 79, 2439-2444.	1.6	22
408	Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 364-370.	1.9	25
409	Clopidogrel Response Variability. <i>American Journal of Therapeutics</i> , 2015, 22, 222-230.	0.9	10
410	Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE). <i>PLoS ONE</i> , 2015, 10, e0121620.	2.5	36
411	Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome. <i>PLoS ONE</i> , 2015, 10, e0132561.	2.5	18
412	A novel biosensor-based microarray assay for the visualized detection of CYP2C19 $\hat{=}$ 2, $\hat{=}$ 3, $\hat{=}$ 4 and $\hat{=}$ 5 polymorphisms. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 217-23.	2.3	0
413	Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1125-1138.	3.5	102
414	Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. <i>Vascular Pharmacology</i> , 2015, 65-66, 17-22.	2.1	6
415	Inhibition of platelet function with clopidogrel, as measured with a novel whole blood impedance aggregometer in horses. <i>Veterinary Journal</i> , 2015, 203, 332-336.	1.7	8
416	Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy. <i>Current Atherosclerosis Reports</i> , 2015, 17, 501.	4.8	3
417	Dual antiplatelet therapy for PCI: Are we tailored to all?. <i>Thrombosis Research</i> , 2015, 135, 1045-1046.	1.7	2
418	The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1599-1617.	3.3	22

#	ARTICLE	IF	CITATIONS
419	Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy W Kardiologii Interwencyjnej, 2015, 1, 19-25.	0.2	10
420	Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. Internal and Emergency Medicine, 2015, 10, 805-814.	2.0	6
421	Is Acute Carotid Artery Stent Thrombosis an Avoidable Complication?. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 2219-2222.	1.6	9
422	Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 226-231.	1.5	21
423	Relative Contributions of von Willebrand Factor and Platelets in High Shear Thrombosis. Journal of Hematology & Thromboembolic Diseases, 2016, 4, .	0.1	6
424	CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. Genetics and Molecular Research, 2016, 15, .	0.2	6
425	Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention. Frontiers in Pharmacology, 2016, 7, 453.	3.5	15
426	Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Therapeutics, 2016, 23, e52-e62.	0.9	11
427	Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-activated phosphoprotein phosphorylation assay and multiple electrode aggregometry. Journal of Thrombosis and Haemostasis, 2016, 14, 282-293.	3.8	17
428	Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial. Scientific Reports, 2016, 6, 31838.	3.3	19
429	Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 567-574.	2.6	9
430	Does Uncontrolled Platelet Activation Promote Coronary Artery Disease? —. JACC: Cardiovascular Imaging, 2016, 9, 855-857.	5.3	4
431	Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders. International Journal of Cardiology, 2016, 204, 196-197.	1.7	17
432	Acute Carotid Stent Thrombosis. Vascular and Endovascular Surgery, 2016, 50, 511-521.	0.7	39
433	Associations of <i>P2Y12R</i> gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Cardiovascular Therapeutics, 2016, 34, 460-467.	2.5	16
434	Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Platelets, 2016, 27, 576-582.	2.3	28
435	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. Journal of Thrombosis and Thrombolysis, 2016, 42, 558-565.	2.1	3
436	Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. Thrombosis and Haemostasis, 2016, 116, 638-650.	3.4	78



#	ARTICLE	IF	CITATIONS
437	Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center. Indian Heart Journal, 2016, 68, 624-631.	0.5	11
438	Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 352-358.	2.6	20
439	Safety and efficacy of a new prophylactic tirofiban protocol without oral intraoperative antiplatelet therapy for endovascular treatment of ruptured intracranial aneurysms. Journal of NeuroInterventional Surgery, 2016, 8, 1148-1153.	3.3	39
440	Clopidogrel Response Variability. Journal of Pharmacy Practice, 2016, 29, 26-34.	1.0	24
441	The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointestinal Endoscopy, 2016, 83, 3-16.	1.0	538
442	The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 255-265.	1.7	16
443	Intravenous administration of tirofiban versus loading dose of oral clopidogrel for preventing thromboembolism in stent-assisted coiling of intracranial aneurysms. International Journal of Stroke, 2017, 12, 553-559.	5.9	21
444	Application of Genetic Testing for CYP 450 Polymorphism to Predict Response to Clopidogrel Inpatient Undergoing PCI. Indian Journal of Cardiovascular Disease in Women WINCARS, 2017, 02, 019-023.	0.1	0
445	Effect of CYP3A4—1G and CYP3A5—3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects. Frontiers in Pharmacology, 2017, 8, 176.	3.5	17
446	Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. Pharmacological Research, 2018, 129, 27-33.	7.1	18
447	Association between P2RY12 gene polymorphisms and adverse clinical events in coronary artery disease patients treated with clopidogrel: A systematic review and meta-analysis. Gene, 2018, 657, 69-80.	2.2	12
448	Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: comparing results of the VerifyNow P2Y12 assay to thromboelastography with platelet mapping. Journal of Neurosurgery, 2018, 129, 1160-1165.	1.6	26
449	A Case Series of 18 Patients Receiving Ticagrelor After Carotid Stenting. Journal of Pharmacy Practice, 2018, 31, 519-521.	1.0	6
450	Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. Journal of Cardiovascular Pharmacology, 2018, 72, 296-302.	1.9	12
451	Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. Pharmacogenetics and Genomics, 2018, 28, 207-213.	1.5	9
452	Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2683-2690.	1.6	1
453	Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets. Molecules, 2018, 23, 374.	3.8	15
454	Individualized antithrombotic therapy in high-risk cardiovascular patients. Personalized Medicine, 2018, 15, 223-236.	1.5	1

#	ARTICLE	IF	CITATIONS
455	High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. <i>Journal of Cardiology</i> , 2019, 73, 51-57.	1.9	11
456	Ticagrelor and Acetylsalicylic Acid after Placement of Pipeline Embolization Device for Cerebral Aneurysm: A Case Series. <i>Canadian Journal of Hospital Pharmacy</i> , 2019, 71, .	0.1	3
457	Prevalence of clopidogrel resistance™ in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study. <i>Open Heart</i> , 2019, 6, e000841.	2.3	11
458	Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. <i>Resuscitation</i> , 2019, 137, 205-212.	3.0	31
459	Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the Tj ETQq0 0 0 rgB1.6 Overlook 10 Tf 50	1.6	0
460	Commentary: Antiplatelet Therapy in Flow Diversion. <i>Neurosurgery</i> , 2020, 86, E231-E233.	1.1	5
461	Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats. <i>Biochemical Pharmacology</i> , 2020, 180, 114142.	4.4	7
462	Commentary: Women With First-Hand Tobacco Smoke Exposure Have a Higher Likelihood of Having an Unruptured Intracranial Aneurysm Than Nonsmokers: A Nested Case-Control Study. <i>Neurosurgery</i> , 2020, 87, E628-E630.	1.1	0
463	Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases. <i>Life Sciences</i> , 2020, 245, 117364.	4.3	15
464	Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices. <i>Artificial Organs</i> , 2021, 45, 38-45.	1.9	4
465	Associations of PER3 polymorphisms with clopidogrel resistance among Chinese Han people treated with clopidogrel. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23713.	2.1	4
466	Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India. <i>Journal of Cardiac Critical Care TSS</i> , 0, , .	0.1	0
467	Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: complication prediction using the VerifyNow P2Y12 assay and thromboelastography with platelet mapping. <i>Journal of Neurosurgery</i> , 2021, 134, 884-892.	1.6	12
468	The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD). <i>Molecules</i> , 2021, 26, 1987.	3.8	30
469	The utility of platelet inhibition testing in patients undergoing Pipeline embolization of intracranial aneurysms. <i>Journal of NeuroInterventional Surgery</i> , 2021, , neurintsurg-2021-017681.	3.3	4
470	Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India. <i>Journal of Cardiac Critical Care TSS</i> , 2021, 5, 108-113.	0.1	1
471	PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study. <i>PLoS ONE</i> , 2021, 16, e0254067.	2.5	1
472	Assessment of therapeutic platelet inhibition in cardiac patients: Comparative study between VerifyNow-P2Y12 and Anysis-P2Y12 assay. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 78, 439-448.	1.7	3

#	ARTICLE	IF	CITATIONS
473	Resistance to Antiplatelet Drugs. , 2010, , 449-464.		1
474	Experimental Antiplatelet Therapy. , 2007, , 1193-1208.		1
475	Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting. Thrombosis and Haemostasis, 2009, 101, 23-30.	3.4	5
476	Platelet function analysis: At the edge of meaning. Thrombosis and Haemostasis, 2009, 101, 217-219.	3.4	9
477	The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions. Anatolian Journal of Cardiology, 2016, 16, 967-973.	0.9	5
478	Antiplatelet Resistance“Fact or Myth?. The American Heart Hospital Journal, 2009, 7, 50.	0.2	1
479	Brain Injury Secondary to Carotid Intervention. Journal of Endovascular Therapy, 2007, 14, 219-231.	1.5	8
480	CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmacogenomics and Personalized Medicine, 2013, 6, 85.	0.7	28
481	Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?. Vascular Health and Risk Management, 2006, 2, 39-48.	2.3	4
482	Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vascular Health and Risk Management, 2009, 5, 965.	2.3	37
483	Genetic Signatures in the Treatment of Stroke. Current Pharmaceutical Design, 2014, 21, 343-354.	1.9	5
484	Novel Strategies in Anti-Platelet Treatment for Coronary Artery Disease. Vascular Disease Prevention, 2009, 6, 75-84.	0.2	5
485	Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2013, 11, 136-167.	1.0	6
486	Pharmacology and Clot. , 2008, , 103-122.		1
487	Clopidogrel Resistance: Current Issues. Journal of Enam Medical College, 2016, 6, 38-46.	0.1	2
488	Effects of Cilostazol on Platelet Activation in Coronary Stenting Patients Who Already Treated with Aspirin and Clopidogrel. Korean Journal of Internal Medicine, 2004, 19, 230-236.	1.7	19
489	Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment. Korean Journal of Internal Medicine, 2018, 33, 522-531.	1.7	11
490	Variable response to antiplatelet therapy: what does it mean to clinicians?. Cleveland Clinic Journal of Medicine, 2007, 74, 49-55.	1.3	4

#	ARTICLE	IF	CITATIONS
491	High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovascular Diagnosis and Therapy, 2013, 3, 23-37.	1.7	25
492	Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults. Indian Journal of Pharmacology, 2016, 48, 350.	0.7	7
493	Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Pharmacology & Pharmacy, 2012, 03, 481-484.	0.7	1
494	Clinical importance of aspirin and clopidogrel resistance. World Journal of Cardiology, 2010, 2, 171.	1.5	52
495	Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. World Journal of Cardiology, 2015, 7, 912.	1.5	29
497	Post percutaneous coronary intervention antiplatelet therapy: Current perceptions, prospects and perplexity. Cardiology Journal, 2011, 18, 712-717.	1.2	5
498	Periprocedural myocardial damage during percutaneous coronary intervention: a point-of-care platelet testing and intravascular ultrasound/virtual histology study. Kardiologia Polska, 2013, 71, 325-333.	0.6	2
499	Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study. Scientific Reports, 2021, 11, 20826.	3.3	4
500	Gene polymorphisms of insulin secretion signaling pathway associated with clopidogrel resistance in Han Chinese population. Journal of Clinical Laboratory Analysis, 2021, 35, e23970.	2.1	4
501	Clopidogrel "resistance" and statin cotreatment "significant for cardiocoronary prevention in real life?". Thrombosis and Haemostasis, 2005, 94, 235-7.	3.4	4
502	Measures of Platelet Activation and Aggregation. , 2006, , 467-485.		1
503	Thrombosen und Gefäßverschlüsse trotz antithrombotischer Therapie. , 2010, , 681-688.		0
504	Prasugrel: Review of its Role in the Management of Arterial Coronary Thrombosis. Clinical Medicine Reviews in Vascular Health, 0, 2, 109-119.	3.0	0
507	Current Status of Pharmacogenetics in Antithrombotic Drug Therapy. , 0, , .		0
508	Importance of pharmacogenetics for therapeutic use of clopidogrel. Racionalna Terapija, 2013, 5, 75-83.	0.1	0
509	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. , 2013, , 469-506.		0
511	Effects of novel quinoid thiosulfonate derivative on ADP-induced platelet aggregation. Bulletin of Taras Shevchenko National University of Kyiv Series Biology, 2014, 68, 36-40.	0.0	0
512	Clopidogrel Resistance: An Emerging Problem. University Heart Journal, 2010, 5, 50-51.	0.0	0

#	ARTICLE	IF	CITATIONS
513	Genetyczne aspekty farmakokinetyki i farmakodynamiki kłopidogrelu. Folia Cardiologica, 2015, 10, 275-282.	0.1	0
515	Genetic Polymorphisms of ABCB1 Gene in Patients Having Resistance to Clopidogrel. World Journal of Cardiovascular Diseases, 2017, 07, 390-398.	0.2	0
516	Pathophysiology, causes and pharmacological study of arterial thrombosis. International Journal of Pharma and Bio Sciences, 2017, 8, .	0.1	0
517	Anterior Communicating Artery Aneurysm: Incidental AcomA Aneurysm, pCONus-assisted Coil Occlusion, Intracerebral Hematoma due to Hyper-response on Aspirin and Clopidogrel. , 2018, , 1-9.		0
518	An Observational Study of the Relationship Between Outcome and Platelet Reactivity in Chinese Patients Undergoing PCI Loading with 600 mg Clopidogrel. Cardiovascular Innovations and Applications, 2020, 5, .	0.3	0
519	Anterior Communicating Artery Aneurysm: Incidental AcomA Aneurysm, pCONUS-Assisted Coil Occlusion, Intracerebral Hematoma due to Hyper-Response on Aspirin and Clopidogrel. , 2020, , 647-655.		0
520	P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention – Understanding the debate on Prasugrel or Ticagrelor. , 2021, , 108029.		2
521	Platelets and new antiplatelet drugs. Therapy: Open Access in Clinical Medicine, 2005, 2, 465-502.	0.2	0
522	The Correlation Between <i>MDR1</i> Gene Polymorphism and Clopidogrel Resistance in People of the Hui and Han Nationalities. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110732.	1.7	3
523	Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients. Scientific Reports, 2022, 12, 6171.	3.3	2
526	Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele. Journal of Thoracic Disease, 2022, 14, 2591-2601.	1.4	5
527	Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. International Journal of Molecular Sciences, 2022, 23, 11317.	4.1	10
528	Dual Antiplatelet Alternatives are Associated With Increased Stroke and Death After Transcarotid Revascularization. Annals of Surgery, 2023, 278, e620-e625.	4.2	1
529	Decreased plasma exposure of clopidogrel active metabolite in rats after long-term treatment with clopidogrel. Biopharmaceutics and Drug Disposition, 0, , .	1.9	0
530	The Platelet Aggregation Inhibition Activity of Polyphenols can be mediated by 67kda Laminin Receptor: A New Therapeutic Strategy For the Treatment of Venous Thromboembolism. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2023, 21, .	1.0	0
531	Current concepts and novel targets for antiplatelet therapy. Nature Reviews Cardiology, 2023, 20, 583-599.	13.7	7
532	The Subtilisin-Like Protease Furin Regulates Hemin-Dependent Ectodomain Shedding of Glycoprotein VI. Thrombosis and Haemostasis, 2023, 123, 679-691.	3.4	2
533	Modifying effect of diabetes on the short-term effect of clopidogrel in patients with myocardial infarction. Heart and Mind (Mumbai, India), 2018, 2, 28.	0.6	0

#	ARTICLE	IF	CITATIONS
534	Effect of cytochrome P450 2C19 (CYP2C19) gene polymorphism and clopidogrel reactivity on long term prognosis of patients with coronary heart disease after PCI. Journal of Geriatric Cardiology, 2024, 21, 90-103.	0.2	0